Preiss, David
Baigent, Colin
Article History
First Online: 3 July 2017
Competing interests
: D.P. consulted for Sanofi on three occasions in 2013–2014 during previous employment. C.B is a member of the independent data and safety monitoring board for trials of evolocumab, of which FOURIER was one.